Synopsis:
In this episode of the Biotech2050 podcast, David Esposito, CEO of ONL Therapeutics, provides valuable insights into the challenges and opportunities in the field of ophthalmology. Esposito's extensive career journey, from the United States Military Academy to leading ONL Therapeutics, underscores his deep understanding of the industry. He offers a comprehensive analysis of the impact of the Inflation Reduction Act (IRA) on indication selection and the evolving capital market for biotech companies. The episode delves into the complexities of proving safety and tolerability in new mechanisms of action, the strategic shift in pursuing chronic indications, and the interplay between big pharma and early-stage biotechs in the current capital environment. Esposito's expertise and in-depth knowledge make this episode essential listening for ophthalmology professionals seeking to navigate industry challenges, understand the IRA's implications, and explore strategic partnerships for clinical development support.,In this episode of the Biotech2050 podcast, CEO of ONL Therapeutics, David Esposito, shares his extensive insights into the challenges and opportunities within the ophthalmology field. With a career spanning from the United States Military Academy to leading ONL Therapeutics, Esposito brings a wealth of experience and understanding to the topic. The discussion delves into the intricate impact of the Inflation Reduction Act (IRA) on indication selection and the dynamic capital market for biotech companies. Esposito's analysis covers the complexities of proving safety and tolerability in new mechanisms of action, strategic shifts in pursuing chronic indications, and the interplay between big pharma and early-stage biotechs in the current capital environment. Professionals in the ophthalmology sector will find this episode invaluable for gaining insights into industry challenges, comprehending the implications of the IRA, and exploring strategic partnerships for clinical development support.
Biography:
David is the former CEO of Armune BioScience where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The Company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017.
David Esposito is an experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers.
He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing and commercial strategy for the US Division.
David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.
